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Strengths and limitations of this study
 ► This study should be relevant for decision- makers at 
the national healthcare level as well as at the clinical 
level.
 ► It is the first economic evaluation of telehealthcare 
in heart failure patients that strictly follows inter-
national guidelines for health economic evaluation 
alongside clinical trials.
 ► Precise assessment of the economic costs was 
allowed through patient specific data and detailed 
registration of operational as well as capital costs 
of telehealthcare.
 ► No evidence was provided, however, on the long- 
term cost- effectiveness or on the explanation of 
what components of the intervention were actually 
effective or whether the effect was contingent on the 
intervention in its entirety.
 ► Trial- based economic evaluations are limited by 
truncated time horizons, difficulty in generalising to 
other settings, and failure to incorporate evidence 
from other trials or observational studies.
AbStrACt
Objective This study aimed to assess the cost- 
effectiveness of telehealthcare in heart failure patients as 
add- on to usual care.
Design A cost- utility analysis was conducted from 
a public payer perspective alongside the randomised 
controlled TeleCare North trial.
Setting The North Denmark Region, Denmark.
Participants The study included 274 heart failure patients 
with self- reported New York Heart Association class II- IV.
Interventions Patients in the intervention group were 
provided with a Telekit consisting of a tablet, a digital 
blood pressure monitor, and a scale and were instructed 
to perform measurements one to two times a week. 
The responsibility of the education, instructions and 
monitoring of the heart failure (HF) patients was placed on 
municipality nurses trained in HF and telemonitoring. Both 
groups received usual care.
Outcome measures Cost- effectiveness was reported as 
incremental net monetary benefit (NMB). A micro- costing 
approach was applied to evaluate the derived savings in 
the first year in the public health sector. Quality- adjusted 
life- years (QALY) gained were estimated using the EuroQol 
5- Dimensions 5- Levels questionnaire at baseline and at a 
1- year follow- up.
results Data for 274 patients were included in the 
main analysis. The telehealthcare solution provided a 
positive incremental NMB of £5164. The 1- year adjusted 
QALY difference between the telehealthcare solution and 
the usual care group was 0.0034 (95% CI: −0.0711 to 
0.0780). The adjusted difference in costs was -£5096 
(95% CI: −8736 to −1456) corresponding to a reduction 
in total healthcare costs by 35%. All sensitivity analyses 
showed the main results were robust.
Conclusions The TeleCare North solution for monitoring 
HF was highly cost- effective. There were significant cost 
savings on hospitalisations, primary care contacts and 
total costs.
trial registration number  ClinicalTrials. gov: 
NCT02860013.
IntrODuCtIOn
Heart failure (HF) is a common chronic 
disease with an estimated global prevalence of 
approximately two per cent.1–3 In Denmark, 
approximately 9000 patients are diagnosed 
with HF each year. The incidence increases 
with higher age, and it has been estimated 
that one in five individuals will develop HF 
during their lifetime.2–4 In total, the condition 
is conservatively estimated to affect approxi-
mately 66 000 citizens in Denmark, and about 
five per cent of all Danish citizens above the 
age of 75 have been diagnosed with HF.4 5 The 
prevalence of HF is, however, expected to rise 
in the future due to, among others, a higher 
prevalence of predisposing factors, such as 
hypertension, diabetes and obesity but also 
due to the increased longevity of patients with 
HF, which is likely the result of an improved 
treatment of the condition.1 2 6
HF symptoms include dyspnoea, fatigue, 
lethargy and oedema.3 4 The severity of 
patients’ HF is often described according 
to the New York Heart Association (NYHA) 
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functional classification system, which may be used by 
patients to classify the severity of their HF according to 
their own experience of the condition. Class I indicates 
that the condition does not limit physical activity and 
that ordinary activity does not cause any symptoms. In 
higher classes, the symptoms reported are increasingly 
more severe; thus, in class IV, patients cannot perform 
physical activity without experiencing symptoms, or they 
experience symptoms even at rest.3 7 HF is believed to 
impair patients’ health- related quality of life (HRQoL) 
compared with individuals without the condition, and the 
condition entails a substantially increased mortality.2 8–10 
In addition to the personal burden that HF entails, the 
condition also causes a substantial burden on healthcare 
systems worldwide, accounting for approximately two per 
cent of total healthcare expenditures.2 11 Hospitalisations 
are recognised as the primary driver for the total costs 
related to HF, though outpatient visits also constitute a 
substantial part.2 12
In 2016, the European Society of Cardiology published 
updated guidelines for the diagnosis and treatment of 
acute and chronic HF,13 emphasising the beneficial impact 
of continuous monitoring of, among others, biomedical 
parameters to enable the detection of the development of 
complications and disease progression that may prompt 
changes to patients’ disease management. In the guide-
lines, telehealthcare is mentioned as a possible means of 
monitoring patients.13 Evidence suggests that telehealth-
care in different forms may be beneficial in the manage-
ment of HF, both for the improvement of patients’ 
HRQoL but also in the prevention of, for example, hospi-
talisations and all- cause mortality.14–16 Findings, however, 
are inconsistent,13 17 which might be ascribed to the fact 
that the components of the investigated telehealthcare 
solutions differ. Effectively, this heterogeneity makes the 
various telehealthcare solutions incomparable in terms 
of their design, effectiveness and, consequently, cost- 
effectiveness.15–17 A number of reviews16–18 have requested 
more high- quality studies of the health economic conse-
quences of telehealthcare interventions. To our knowl-
edge, however, up until now, no cost- effectiveness analyses 
of telehealthcare in HF patients have been conducted 
according to international good practice guidelines for 
the economic evaluation alongside clinical trials.19 20
In Denmark, a national strategy has been formulated 
for the introduction of telehealthcare as a means of 
reducing healthcare costs while also providing patients 
with greater HRQoL and the feeling of improved control 
of their disease.21 22 In this respect, the North Denmark 
Region has played a major role in the formulation of the 
national strategy by performing prelaunch, large- scale 
randomised controlled trials and health economic evalu-
ations and national business cases as decision- support for 
the nationwide implementation.23 24 In the wake of the 
first TeleCare North trial directed at patients suffering 
from chronic obstructive pulmonary disease (COPD), 
which was executed in 2014 to 2015,23 24 the TeleCare 
North Heart Failure (HF) trial was launched in 2016 
with the purpose of evaluating the effectiveness and 
cost- effectiveness of a telehealthcare solution directed at 
patients with HF.25 The purpose of this economic evalu-
ation is to evaluate the cost- effectiveness of the TeleCare 
North HF solution, comparing the impact on costs and 
effects (ie, quality- adjusted life- years (QALYs)) with that 
of the usual practice for the treatment of HF in Denmark.
MethODS
The cost- utility analysis was conducted in accordance 
with international guidelines for health economic eval-
uations alongside clinical trials.19 20 26 All clinical and 
cost data for the analysis were collected alongside the 
TeleCare North HF trial, and the time horizon for the 
analysis was restricted to a 1- year period. A Danish public 
healthcare sector perspective was applied, including costs 
accumulating under the auspices of the regional health-
care (ie, pre- hospital services and inpatient and outpa-
tient services in somatic and psychiatric healthcare), 
municipality- based health and social care (eg, home care 
services and rehabilitation) and primary healthcare (eg, 
general practice and physiotherapy) and costs associated 
with purchases of prescription medicine at Danish phar-
macies. Costs associated with patient- paid or relative- paid 
transportation and productivity costs were not included.
The trial protocol presenting the design of the Tele-
Care North HF Trial and associated economic evalua-
tion has previously been published.25 The participants in 
the intervention group received patient education and 
telehealthcare equipment for continuous monitoring of 
physiological measurements. Patients in the intervention 
group were provided with a Telekit consisting of a tablet, 
a digital blood pressure monitor and a scale, and were 
instructed to perform measurements one to two times a 
week. The responsibility for the education, instructions 
and monitoring of the HF patients was placed on munic-
ipality nurses trained in HF and telemonitoring. The 
nurses were given the authority to intervene and change 
medication if, for instance, measurements indicated a 
deterioration in the patient’s health. The specialised 
nurses could contact the heart failure clinic at the central 
university hospital for guidance regarding specific patient 
issues. Patients in the control group received the usual 
care, where general practitioners were responsible for the 
monitoring of the patients (see the online supplementary 
appendix A for elaboration).
The result of the economic evaluation is expressed 
as the incremental net monetary benefit (NMB) = 
( QALY× Rt− Cost ),
27 where ΔQALY is the incremental 
health- related benefit and ΔCost is the incremental costs. 
Under the assumption of a cost- effectiveness threshold 
(Rt) of £20 000 per QALY gained, an incremental NMB >0 
indicates that the telehealthcare solution is cost- effective 
compared with the usual care.26
The cost- effectiveness of the telehealthcare solution 
is estimated for a 12- month period starting 30 days after 
participant enrolment in the study. This 30- day ‘blanking 
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period’ for both groups was introduced from the day of 
referral to accommodate that participants in the interven-
tion group would only receive the telehealthcare solution 
belatedly compared with the referral date and there-
fore effectively did not receive any intervention in this 
period. The difference in follow- up length was accom-
modated for in the estimation of cost and effect accu-
mulation by weighting the accumulation by the lengths 
of the follow- up of individual participants to represent 
a 12- month follow- up. The enrolment period started on 
1 September 2016 and the follow- up period ended on 4 
March 2018.
Cost accumulation
All costs are presented in 2018 values in British Pounds 
Sterling (£). The Danish consumer price index for health-
care products and services28 was used to adjust the cost 
data from 2016 and 2017 to the price level in 2018. Costs 
were estimated in Danish Krone (DKK) and subsequently 
converted, based on a conversion rate of DKK 827.19 per 
£100 from 31 December 2018.29
healthcare service use and healthcare costs
Patient- specific costs related to healthcare service use 
were estimated based on register data. In Denmark, all 
citizens are provided with a unique personal identifica-
tion number at birth or immigration, which enables the 
linkage of information from various registers at the indi-
vidual level. Information on patients’ gender, birthday, 
migration status and vital status was retrieved from the 
Danish Civil Registration System.30
Information on patients’ use of prescription medicine 
was retrieved from the Danish National Prescription 
Registry. The costs related to prescription medicine were 
valued at pharmacy selling prices excluding value added 
tax.
Patients’ contacts with general practice were iden-
tified through the National Health Insurance Service 
Register.31 32 The costs associated with the contacts to 
general practice are registered in the registry and based 
on fees quoted in a collective agreement negotiated with 
the Danish Medical Association.33
Information on patient hospitalisations was retrieved 
from the Danish National Patient Registry, which holds 
information on all inpatient, outpatient and emer-
gency hospitalisations in somatic and psychiatric wards 
in Denmark.34 In the registry, each contact is valued 
according to the designated diagnosis- related group used 
for reimbursement, the actual procedures performed 
and the length of stay in relation to the contact.
Estimates of the resource consumption of community 
care services in the municipalities were based on detailed 
registrations from 4 of the 11 contributory municipalities 
(the administrative units for tax- financed local health and 
social care). For patients in both groups, registrations 
included all local care activities, such as personal care, 
practical help, home nursing, rehabilitation and tele-
healthcare activities. To increase generalisability to other 
settings in Denmark, the registered time consumption 
for standard care activities was valued using the national 
average effective hourly wage of the municipality nurses 
without managerial responsibility.35 Time consumption 
in relation to rehabilitation consisting of physiotherapy 
was valued using the national average effective hourly 
wage of the municipality and regional physiotherapists 
without managerial responsibility.35 Days of respite care 
in relation to rehabilitation were valued according to the 
estimated expenses of a day in care homes (see online 
supplementary appendix B).36 37
Information on trial participants’ healthcare service 
use and healthcare costs was retrieved for 12 months 
following their individual study start- up date (30 days 
after the date of their enrolment). Information on health 
service use and healthcare costs was retrieved for the 
participants from 12 months before the study start date 
for each participant to control for differences in health-
care utilisation before the start of the intervention.
telehealthcare intervention costs
The administrative office for TeleCare North provided a 
detailed registration of all intervention costs (see online 
supplementary appendix B). Capital costs included the 
development of software and hardware modifications for 
the Telekit, the delivery of and the Telekit itself and one- 
time start- up costs related to the education of patients 
and healthcare professionals. In the analysis, capital costs 
were annuitised over a period of 5 years with a discount 
rate of four per cent per annum and included as equiv-
alent annual costs. The useful equipment lifetime and 
applied discount rate are in accordance with what applies 
for ‘other information technology equipment’ in Danish 
capital accounting.38 39 Operational costs included, among 
other things, maintenance, support and licenses. The 
daily work with continuous monitoring of the patients was 
included in the municipalities’ registrations of healthcare 
service use and healthcare costs described above.
Software development and hardware configura-
tion were valued as prices paid to an external supplier, 
reflecting actual tenders. The Telekit was valued based on 
the expected purchase price if the intervention were to 
be implemented and used in real- life practice following 
the results of the TeleCare North HF trial. The delivery 
of hardware, running costs related to licenses, handling 
of assets, data charges and substitution of malfunctioning 
equipment were valued as the price negotiated and paid 
to the external supplier.
Before the trial, various meetings and educational semi-
nars were held to train healthcare professionals in the use 
of the telehealthcare solution and monitoring duties and 
to increase their general knowledge on the management 
of HF, rehabilitation and palliation. Participants in these 
meetings and seminars included general practitioners 
and regional and municipality nurses. In addition, meet-
ings were held informing project managers, key persons 
and healthcare professionals on the telehealthcare solu-
tion and the implementation of the intervention. The 
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per- patient costs of educating healthcare professionals and 
others were estimated based on the planned time spent 
in the meetings, the number of participants at the meet-
ings and the average effective hourly wage of the partic-
ipants. The applied average effective hourly wages were 
estimated based on national average wages to increase 
generalisability to the other regions in Denmark.35
Costs of modifications of the hardware, software devel-
opment and education for healthcare professionals 
and management staff were allocated to all HF patients 
who would be offered the telehealthcare solution in the 
North Denmark Region. The number of HF patients in 
the North Denmark Region was estimated to be 6700, 
given an estimated prevalence of 66 000 HF patients in 
Denmark4 and that approximately 10% of the Danish 
population resides in the North Denmark Region.
The annual operational costs of telehealthcare were 
allocated to the estimated number of HF patients and 
other patients using the regional telehealth system in the 
North Denmark Region (10 500 patients24). The opera-
tional costs were valued as prices paid.
Measure of effectiveness
Information on patients’ HRQoL was collected from 
questionnaires at baseline and at the end of the follow- up. 
Index scores for participants’ HRQoL were estimated 
based on the EuroQol 5- Dimensions 5- Levels (EQ- 5D- 5L) 
questionnaire. Currently, however, there are no Danish 
societal weights estimated for the EQ- 5D- 5L questionnaire 
for which reason the responses in the EQ- 5D- 5L ques-
tionnaire were used to predict responses in the EuroQol 
5- Dimensions 3- Levels (EQ- 5D- 3L) questionnaire by 
applying a response mapping approach.40 41 Danish soci-
etal weights for the EQ- 5D- 3L questionnaire were subse-
quently applied.42 Information on mortality was retrieved 
from the Danish Registry of Causes of Death, which holds 
information on all causes of death in Denmark. Informa-
tion on participants’ HRQoL and relevant demographic 
characteristics were collected at baseline at participant 
enrolment in the outpatient clinics or after the partici-
pant returned home, if preferred by the patient.25 Irre-
spective of where the data were collected, the time of 
collection was dated to be 30 days after the date of their 
enrolment. At the end of the follow- up, the EQ- 5D- 5L 
questionnaire was sent in paper form to patients’ home 
addresses from the trial administration office. A prepaid 
return envelope was included. The response was dated to 
the end of follow- up (4 March 2018).43
Linear interpolation of the utility scores from baseline 
to follow- up was performed to estimate the QALY gain 
and was scaled to represent the QALY gain within 1 year. 
The utility score for patients who died during follow- up 
was set to 0 at the time of death.
Analysis
Missing data management
In accordance with good research practice guidelines 
within effectiveness and cost- effectiveness studies, the 
primary analysis was performed according to the intention- 
to- treat principle and imputation was performed to 
account for missing data.19 20 44 45 Imputations of missing 
data for the primary analysis was performed in accordance 
with the methods for multiple imputations described by 
Faria et al.20 A full description of the imputation approach 
is provided in the online supplementary appendix C.
In total, 299 participants were enrolled in the trial 
(intervention group n=145, control group n=154) 
(see figure 1). One patient was enrolled but was never 
randomised to any treatment group and, therefore, not 
included in the study. Four patients did not return ques-
tionnaires at either baseline or follow- up due to with-
drawal shortly after enrolment for which reason no data 
were available on them except basic registry information. 
As no effectiveness data were available for these patients 
and they did, de facto, not participate in the study, they 
were excluded from analyses in accordance with guide-
lines on post- randomisation exclusion.46 Furthermore, 
21 patients with a self- reported NYHA I classification 
were wrongfully included in the randomisation. Given 
the eligibility criteria of the trial, these patients were 
excluded from the primary analysis. For the primary anal-
ysis, the intervention group included 134 patients, and 
the control group included 140 patients.
Cost-utility analysis
For descriptive statistics, all data are reported as means 
and SEs, and differences in means between the interven-
tion and the control group are presented as raw, unad-
justed differences. P values for between- group differences 
have been evaluated by a Student’s t- test for continuous 
variables and a Pearson’s X2 test for binary and multino-
mial variables. Statistical significance was assumed for p 
values<0.05, and all significance tests were two- tailed.
The estimates of incremental costs and QALYs between 
the intervention group and the control group were 
based on a seemingly unrelated regression analysis. This 
regression method is recommended and widely used in 
economic evaluation because cost and HRQoL is normally 
correlated.47 In the primary analysis, both total costs and 
QALYs were adjusted for group allocation, age, gender, 
baseline EQ- 5D- 3L summary score, total costs in the year 
preceding the study start date, self- reported NYHA classi-
fication at baseline, the self- reported length of HF diag-
nosis at study start, education level, relationship status and 
the presence of self- reported smoking, diabetes mellitus, 
psychological disorder, COPD, cancer and musculoskel-
etal disorder. The estimations were performed using the 
mi estimate, cmdok: sureg command in Stata.
The deterministic incremental NMB was estimated 
using the treatment beta coefficients from the seem-
ingly unrelated regressions, and a probabilistic sensitivity 
analysis was performed to evaluate the decision uncer-
tainty. A scatter plot of incremental cost- effectiveness was 
generated based on 10 000 simulations. The simulations 
were based on random draws from the estimated treat-
ment effect on cost and QALY accumulation and their 
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Figure 1 Flowchart of exclusion of patients for the economic evaluation.
associated SEs. The incremental costs were expected 
to assume a gamma distribution and the QALYs were 
expected to assume a Gaussian distribution.
All statistical analyses were performed in Stata, V.15.1.
Sensitivity analyses
Both the primary analysis and sensitivity analyses were 
performed with and without adjustment. For determin-
istic sensitivity analyses, three different scenarios were 
investigated;
Scenario I: A complete case analysis, that is, an analysis 
in which information on all outcome variables and vari-
ables used for adjustment were available.
Scenario II: An analysis including all patients that 
were enrolled in the study, including patients with a self- 
reported NYHA classification of I.
Scenario III: To evaluate whether results were driven by 
a minority of patients with very high resource consump-
tion, a sensitivity analysis was performed in which the 
upper 10 per cent of patients with the highest resource 
consumption before imputation were excluded before 
imputation.
Scenario analysis II and III were both based on imputed 
data sets.
Patient and public involvement
Patient and public involvement in the project was organ-
ised by the TeleCare North project organisation placed 
within the regional healthcare administration. This 
included open seminars/meetings with patients, rela-
tives, healthcare providers and others. A special home-
page was designed with relevant information for patients 
and relatives, hospitals, municipalities and general practi-
tioners, respectively. The TeleCare North project organi-
sation also organised the development of the educational 
programme for patients and healthcare providers in all 
sectors. The research- based evaluation of the project 
was presented in public for all interested citizens free of 
charge. At the local political and public administrative 
levels, the project was followed and discussed in relevant 
fora with participation from all municipalities and the 
region.
reSultS
There were no statistically significant differences in base-
line characteristics between the two groups, and missing-
ness in variables was also fairly distributed between them 
(table 1).
Within the 1- year follow- up, the group receiving the 
telehealthcare solution had a consistently lower resource 
consumption across all healthcare cost categories 
compared with the group receiving usual care, leading 
to a total raw difference of -£5668 (table 2). Thus, the 
usage of telemedicine reduces total healthcare costs by 
35% (5668 off a base of 16 241 BritishPounds Sterling). 
This lower mean cost per patient was primarily driven by 
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Table 1 Participant baseline characteristics. P values for differences have been evaluated by Student’s t- test for continuous 
variables and Pearson’s X2 test for binary and multinomial variables
Study population Telehealthcare solution Control group
Raw between- group 
difference
P value for 
difference
No of patients, n (%) 134 (49 %) 140 (51 %)
Age, mean (SD), y* 67.21 (11.51) 67.30 (11.78) −0.09 0.95
Sex, female, %* 18.91 (n=24) 20.71 (n=29) −1.8 0.56
Relationship status     0.14
  Missing, % 1.49 (n=2) 0.71 (n=1)
  Living with somebody, % 75.76 (n=100) 67.63 (n=94) 8.13
  Living alone, % 24.24 (n=32) 32.37 (n=45) −8.13
Education     0.67
  Missing, % 2.23 (n=3) 1.43 (n=2)
  Primary (<3 years), % 65.65 (n=86) 68.12 (n=94) −2.47
  Secondary (>3 years), % 34.35 (n=45) 31.88 (n=44) 2.47
Smoking, (yes)* % 23.31 (n=31) 17.14 (n=24) 6.17 0.20
Self- reported duration of HF     
  Missing, % 5.97 (n=8) 6.43 (n=9)
  Mean (SD), y 5.27 (7.45) 5.47 (7.13) −0.20 0.82
  Median, y 2 2 0
NYHA score at baseline, mean (SD) 2.55 (0.69) 2.50 (0.61) 0.05 0.53
  Missing, % 4.48 (n=6) 5.00 (n=7)
  NYHA class II, % 56.25 (n=72) 56.39 (n=75) −0.14
  NYHA class III, % 32.81 (n=42) 37.59 (n=50) −5.41
  NYHA class IV, % 10.94 (n=14) 6.02 (n=8) 4.92
Self- reported comorbidity, %* 41.04 (n=55) 41.43 (n=58) −0.39 0.95
  Diabetes, % 13.43 (n=18) 19.29 (n=27) −5.86 0.19
  COPD, % 16.42 (n=22) 15.71 (n=22) 0.71 0.87
  Psychological disorder, % 2.24 (n=3) 2.14 (n=3) 0.10 0.96
  Musculoskeletal disorder, % 16.42 (n=22) 15.71 (n=22) 0.71 0.87
  Cancer, % 6.72 (n=9) 7.14 (n=10) −0.42 0.89
Baseline EQ- 5D- 3L index score, 
mean (SD)
0.7073 (0.1514) 0.7078 (0.1465) 0 0.98
  Missing, % 5.22 (n=7) 0.7 (n=1)
Baseline historical costs excluding 
municipality costs (£), mean (SD)*
18 587.52 (21 605.38) 19 560.00 (23 491.52) −972.48 0.72
Baseline historical municipality 
costs (£), mean (SD)
122.24 (303.18) 479.88 (1585.97) −357.64 0.07
  Missing, % 49.25 (n=66) 50.71 (n=71)
*Variable has no missing values.
£, British Pounds Sterling; COPD, chronic obstructive pulmonary disease; EQ- 5D- 3L, EuroQol 5- Dimensions 3- Levels; HF, heart failure; 
NYHA, New York Heart Association.
lower costs associated with hospitalisations (intervention 
group £5055 vs control group £9064, p value=0.01).
In the primary analysis, the 1- year adjusted QALY 
difference between the telehealthcare solution and the 
usual care group was 0.0034 (95% CI: −0.0711 to 0.0780), 
indicating an insignificant gain in HRQoL for patients 
receiving the telehealthcare solution (table 3). The 
adjusted baseline utility score was similar across the two 
groups (0.7079 for control and 0.7075 for intervention). 
The mortality was similar between both groups, with five 
deaths in the control group and seven deaths in the inter-
vention group.
The adjusted difference in costs was -£5096 (95% CI: 
−8736 to −1456), indicating a significantly lower total 
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Table 2 Unadjusted mean costs per patient in the intervention group and the control group, respectively, partitioned into cost 
categories over the 12- month follow- up (2018 £). For all cost categories, data are complete except for the municipality costs of 
which 50% missing (n=137). The costs associated with the telehealthcare solution is based on deterministic estimates
Cost category
Mean costs (SE), £
Telehealthcare 
solution
(n=134)
Control group 
(n=140)
Raw between- group 
difference (£)
P value for 
difference
Hospital contacts         
  Hospitalisations 5055.13 (1027.31) 9063.65 (1217.95) −4008.52 0.01
  Outpatient contacts 3163.53 (264.85) 4191.29 (644.82) −1027.76 0.15
  Psychiatric outpatient contacts 13.72 (5.95) 62.46 (39.20) −48.74 0.23
Primary care contacts 469.26 (44.37) 600.36 (40.43) −131.10 0.03
Pharmacy purchases 972.25 (94.01) 1076.57 (81.31) −104.32 0.40
Municipality costs (home care, 
rehabilitation, monitoring in relation to the 
telehealthcare solution, etc)
681.61 (137.16) 1246.88 (461.78) −565.27 0.25
Healthcare costs, excluding costs of the 
telehealthcare solution
10 355.50 16 241.21 −5,885.71 0.01
Costs of the telehealthcare solution, 
excluding costs of monitoring:
        
Software development and support*/† 0.27 0 0.27   
Basic operation: surveillance, support of 
health professionals, server licenses, etc‡
8.47 0 8.47   
Running development of apps, system 
updates, etc‡
1.76 0 1.76   
Education of healthcare professionals*/† 3.04 0 3.04   
Telekit, including initial delivery and patient 
education*
122.36 0 122.36   
Annual operational costs: licenses, sim 
card data, substitution of faulty equipment, 
etc
82.15 0 82.15   
Total costs (including costs of the 
telehealthcare solution)
10 573.55 16 241.21 −5,667.66 0.01
*Annuitised over a 5- year period with a discount rate of four per cent.
†Costs divided among the expected number of HF patients in the North Denmark Region (6700 patients).
‡Costs divided among the expected number of HF and COPD patients in the North Denmark Region (10 500 patients24). See appendix B for 
further information.
£, British Pounds Sterling; apps, applications; COPD, chronic obstructive pulmonary disease; HF, heart failure.
mean cost per patient in the telehealthcare solution 
group. Based on the incremental cost and QALY esti-
mates and an assumed cost- effectiveness threshold of 
£20 000 per QALY,27 the telehealthcare solution provides 
a positive incremental NMB of £5164, indicating that the 
telehealthcare solution is cost- effective. The unadjusted 
analysis also indicates that the telehealthcare solution 
provides a significant cost saving (-£5539 (95% CI: −9483 
to −1595)) and an insignificant impact on patients’ QALY 
gain (−0.0005 (95% CI: −0.0723 to 0.0714)) and therefore 
is cost- effective (NMB = £5530). The result of the prob-
abilistic sensitivity analysis is shown in the incremental 
cost- effectiveness scatter plot in figure 2. The incre-
mental cost- effectiveness distribution disperses across 
the southwest and southeast quadrant of the incremental 
cost- effectiveness plane in agreement with the QALY gain 
associated with the telehealthcare solution being insignif-
icant but the incremental negative cost being significant.
All scenario analyses showed the same result with tele-
healthcare associated with lower costs and an insignificant 
impact on patients’ HRQoL (table 3). Across the adjusted 
and unadjusted sensitivity analyses, the cost- effectiveness 
result is relatively robust, with all analyses indicating a 
positive incremental NMB of the telehealthcare solution 
compared with usual practice.
DISCuSSIOn
The principal finding of this study is that the investi-
gated telehealthcare solution is highly cost- effective for 
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Table 3 Incremental costs (£) and quality- adjusted life years after 12- month follow- up
Scenario N
Incremental costs, £ 
(95% CI) Incremental QALYs (95% CI)
Net 
monetary 
benefit, £*
Primary analysis, adjusted† 274 −5095.92
(−8736.33 to −1455.51)
0.0034
(−0.0712 to 0.0780)
5163.98
Primary analysis, unadjusted‡ 274 −5539.10
(−9483.26 to −1594.95)
−0.0005
(−0.0723 to 0.0714)
5530.04
Scenario I:
  Complete case analysis, adjusted† 89 −1609.85
(−7036.27 to 3816.57)
−0.0239
(−0.0605 to 0.0127)
1131.62
  Complete case analysis, 
unadjusted‡
94 −2752.84
(−8438.59 to 2932.91)
−0.0157
(−0.0536 to 0.0221)
3570.69
Scenario II:
  Incl. NYHA class I patients, 
adjusted†
295 −4572.69
(−8030.66 to −1114.73)
−0.0037(-0.0736 to 0.0663) 4498.88
  Incl. NYHA class I patients, 
unadjusted‡
295 −4857.43
(−8587.98 to −1126.88)
−0.0061 (-0.0730 to 0.0609) 4736.20
Scenario III:
  Excl. top 10th percentile resource- 
heavy patients, leaving out 
municipality costs, adjusted†
247 −3060.50
(−4836.08 to −1284.93)
−0.0096 (-0.0949 to 0.0756) 2867.62
  Excl. top 10th percentile resource- 
heavy patients, leaving out 
municipality costs, unadjusted‡
247 −3181.34
(−5103.28 to −1259.40)
−0.0130 (-0.0944 to 0.0683) 2921.12
*Estimated based on an expected cost- effectiveness threshold of £20 000 per QALY.
†Seemingly unrelated regression, adjustment for group allocation, age, gender, baseline EQ- 5D- 3L summary score, total costs in the year 
preceding the study start date, self- reported NYHA classification at baseline, the self- reported length of HF diagnosis, education level, 
relationship status and the presence of self- reported smoking, diabetes mellitus, psychological disorder, COPD, cancer and musculoskeletal 
disorder.
‡Seemingly unrelated regression with intervention group as the only predictor.
£, British Pounds Sterling; COPD, chronic obstructive pulmonary disease; EQ- 5D- 3L, EuroQol 5- Dimensions 3- Levels; Excl., excluding; HF, 
heart failure; Incl., including; NYHA, New York Heart Association; QALYs, Quality- adjusted life- years.
Figure 2 Incremental cost- effectiveness scatter plot based on the probabilistic sensitivity analysis. The dotted line indicates a 
cost- effectiveness threshold of £20 000 per quality- adjusted life- year (QALY).
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the treatment of HF patients in the Danish setting. High- 
quality economic evaluations of telehealthcare solutions 
in the management of HF have been requested16–18 and, 
to our knowledge, the present study is the first economic 
evaluation of telehealthcare in HF patients that strictly 
follows international guidelines for health economic 
evaluation alongside clinical trials.19 Thus, a particular 
strength of this study was the micro- costing approach, 
including the availability of information on patient- 
specific resource usage from the Danish registers. The 
majority of information on patients’ resource consump-
tion was retrieved from well- validated Danish registers, 
ensuring the validity of the registrations with no missing 
data in these parameters. For the resource consumption 
in the municipalities, data from 4 out of the 11 participa-
tory municipalities were applicable. The four municipali-
ties were relatively large (making for approximately 50% 
of the total participant sample), and thus, the representa-
tiveness of their organisation and consequently costs for 
smaller municipalities is debatable. However, municipality 
costs only constitute a minor share of the total costs (cf. 
table 3); for which reason it could be suspected that even 
if the estimate of municipality costs is not representative 
for all participatory municipalities, the cost- effectiveness 
conclusion would not be markedly affected.
In the present cost- utility analysis, the impact on 
patients’ QALY gain was insignificant across all analyses. 
The increased sensitivity, which could have been achieved 
by using the 5- L questionnaire,19 may effectively have 
been watered down when predicting the 3- L responses 
from the 5- L responses and applying the 3- L weights. This 
might provide an explanation of why it was not possible 
to observe any substantial differences in QALY accumu-
lation between the two intervention groups, which could 
otherwise have been expected given findings in previous 
studies.16
In general, telehealthcare interventions and the studies 
of them are relatively heterogeneous, making a compar-
ison of them difficult.15 16 In a Cochrane review from 
2015,16 structured telephone support and telemonitoring 
for HF patients were found to reduce all- cause mortality 
and HF- related hospitalisations. In addition, the impact 
on patients HRQoL and cost accumulation was incon-
sistent, emphasising the difficulties of evaluating and 
comparing the cost- effectiveness of telehealthcare inter-
ventions aggregately.16
Only a few papers report on cost savings in relation to 
telehealthcare within this field. These studies do not have 
economic evaluation as their primary aim and do not 
strictly follow proper practice guidelines for economic 
evaluations.19 26 Nevertheless, they all point in the same 
direction of potentially huge savings.16–18 Frederix et al48 
reported insignificant long- term savings of approximately 
27% from an initial 6 month telehealthcare intervention. 
Jiménez- Marrero et al49 report savings of approximately 
38% for a subgroup of HF patients with a left ventricular 
ejection fraction >40. Comín- Colet et al50 report savings 
of approximately 45%, mainly driven by a significant 
reduction in hospitalisations between the telehealth-
care group and control group. An economic modelling 
study by Liu et al51 also points in the same direction 
of possible savings from telehealthcare interventions 
directed at intermediate- risk and high- risk patients over 
a 1- to 5- year window. Their results suggest the economic 
viability of telehealthcare programme for the manage-
ment of chronic HF, but emphasised the importance 
of risk stratification in such programme.51 In our study, 
however, the severity of HF did not seem to be important, 
as there appeared to be only minor differences in cost 
savings depending on whether patients reporting being 
in NYHA class I were included or not. A particular differ-
ence between our study and other studies may also have 
been the level of organisational learning and knowledge 
management, as the TeleCare North trial builds on many 
years of experience with telehealthcare solutions from 
previous trials23 24 as well as the national implementation 
of telehealth programme for COPD in Denmark decided 
in 2015.22
As the design of the TeleCare North HF trial and the 
components of the telehealthcare intervention was 
somewhat similar to that of the TeleCare North COPD 
trial,23 25 the present study anticipated that the economic 
evaluation would essentially produce results similar to 
that of Udsen et al.24 In agreement with the economic 
evaluation by Udsen et al,24 no significant difference in 
QALY accumulation between the intervention groups 
was observed in this study. In contrast, the present study 
found telehealthcare to produce substantial cost savings, 
which contrasts with the added costs associated with tele-
healthcare found by Udsen et al.24 The difference is that 
telehealthcare is cost- effective for HF patients but not all 
COPD patients. This discrepancy indicates that the cost- 
effectiveness of telehealthcare interventions, to a large 
degree, depends on the recipient patient group, making 
it difficult to comment on the cost- effectiveness of tele-
healthcare interventions as a whole. The characteristics 
of specific patient groups ought, therefore, to be incor-
porated when telehealthcare interventions are designed 
and implemented.
The impact of the TeleCare North solution of patients 
quality of life measured with the Short- Form 36 (SF-36) 
questionnaire’s physical and mental component 
summary scores and the Kansas City Cardiomyopathy 
Questionnaire 12 score are published elsewhere.52 It 
was only possible to detect a small but significant posi-
tive change in the SF-36 mental component summary 
score. Thus, with respect to the impact on patients’ 
HRQoL, the telehealthcare solution cannot be char-
acterised as an unqualified success. It could, however, 
be hypothesised that the currently applied methods of 
measurement of effect are too insensitive to detect any 
beneficial impact especially on patients’ mental well- 
being, as suggested by the positive impact on the SF-36 
mental component summary score but none of the 
other measures. It is possible that the positive impact of 
telehealthcare does not manifest itself as an impact on 
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patients’ HRQoL but rather their opinions and beliefs, 
which subsequently affects their healthcare- seeking 
behaviour.
Given the complexity and multiple purposes of the 
intervention under investigation,25 it is possible that 
conventional measures of effectiveness, such as HRQol 
and QALY, do not sufficiently capture all potential effects. 
It is possible that impacts on other parameters could 
have been observed, such as patients’ satisfaction, self- 
perceived risk of dying, comfort, ability to reduce anxiety 
through telephone contact with a well- known local nurse 
and an increased sense of capability among others. It 
could be considered whether the slightly narrow focus on 
patients’ HRQoL and QALY in the present analysis repre-
sent an appropriate evaluation approach to this partic-
ular kind of complex intervention.
Though the present economic evaluation found the 
telehealthcare solution to be highly cost- effective, ques-
tions remain as to why this result was achieved. Thus, it 
remains unclear what components of the intervention 
were actually effective or whether the effect is contingent 
on the intervention in its entirety. In the design phase 
of future trials on the effectiveness and cost- effectiveness 
of complex interventions such as telehealthcare, early 
consideration of mechanisms of action and programme 
theory53 ought to be introduced to improve our under-
standing of why some interventions may prove effective 
and cost- effective and others not. This may increase the 
cost- effectiveness of future telehealth solutions.
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